Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
Top Cited Papers
- 1 June 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (16), 1997-2003
- https://doi.org/10.1200/jco.2012.45.6095
Abstract
Purpose HER2 mutations are identified in approximately 2%of non–small-cell lung cancers (NSCLC). There are few data available that describe the clinical course of patients with HER2-mutated NSCLC. ...Keywords
This publication has 21 references indexed in Scilit:
- Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung AdenocarcinomasClinical Cancer Research, 2012
- Characteristics of lung cancer in women: Importance of hormonal and growth factorsLung Cancer, 2012
- Chipping away at the lung cancer genomeNature Medicine, 2012
- Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast CancerJournal of Clinical Oncology, 2009
- HER2 YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapyProceedings of the National Academy of Sciences, 2009
- Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar featuresInternational Journal of Cancer, 2006
- Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272Cancer Research, 2006
- Somatic Mutations of the HER2 Kinase Domain in Lung AdenocarcinomasCancer Research, 2005
- Intragenic ERBB2 kinase mutations in tumoursNature, 2004
- HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancerAnnals of Oncology, 2001